{"id":"iv-abatacept","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Infection (upper respiratory, urinary tract)"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Hypertension"},{"rate":"2-5","effect":"Serious infections"}]},"_chembl":{"chemblId":"CHEMBL1201823","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Abatacept (CTLA4-Ig) acts as a selective costimulation modulator that interrupts the second signal required for full T-cell activation. By binding to CD80 and CD86 molecules on antigen-presenting cells, it prevents interaction with CD28 on T cells, effectively suppressing the adaptive immune response. This mechanism makes it particularly useful in autoimmune conditions where T-cell-mediated inflammation drives disease pathology.","oneSentence":"Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:33:32.833Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Polyarticular juvenile idiopathic arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Systemic lupus erythematosus"}]},"trialDetails":[{"nctId":"NCT07388563","phase":"PHASE1","title":"Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Lymphoma, T Cell, Peripheral, T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":20},{"nctId":"NCT00920972","phase":"PHASE1, PHASE2","title":"Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2001-12","conditions":"Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies","enrollment":220},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT05017545","phase":"PHASE1, PHASE2","title":"Carfilzomib and Belatacept for Desensitization","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-12-28","conditions":"Highly Sensitized Prospective Kidney Transplant Recipients","enrollment":21},{"nctId":"NCT03929601","phase":"PHASE2","title":"Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2023-10-30","conditions":"Type 1 Diabetes Mellitus","enrollment":74},{"nctId":"NCT03504241","phase":"PHASE1","title":"Tolerance by Engaging Antigen During Cellular Homeostasis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-30","conditions":"Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient","enrollment":8},{"nctId":"NCT05782335","phase":"","title":"Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":72},{"nctId":"NCT05621759","phase":"PHASE2","title":"Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-09-07","conditions":"Graft Vs Host Disease","enrollment":27},{"nctId":"NCT06008808","phase":"PHASE1","title":"Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-05-07","conditions":"Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease","enrollment":41},{"nctId":"NCT03128996","phase":"PHASE1, PHASE2","title":"Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-03-20","conditions":"Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders","enrollment":29},{"nctId":"NCT04477629","phase":"PHASE2","title":"Belatacept in De Novo Heart Transplantation","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2020-08-06","conditions":"Heart Transplantation","enrollment":12},{"nctId":"NCT07238712","phase":"PHASE2","title":"Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor","status":"RECRUITING","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2025-05-10","conditions":"Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia, Myelodysplastic Syndromes (MDS)","enrollment":60},{"nctId":"NCT05335928","phase":"PHASE3","title":"Abatacept in Immune Checkpoint Inhibitor Myocarditis","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-07-02","conditions":"Myocarditis Acute, Cancer","enrollment":390},{"nctId":"NCT05822583","phase":"PHASE4","title":"Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2023-07-06","conditions":"COVID-19","enrollment":285},{"nctId":"NCT03457142","phase":"PHASE2","title":"Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2018-09-11","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":15},{"nctId":"NCT04046549","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-10-30","conditions":"Allografts, Rejection; Transplant, Kidney, Transplant Rejection","enrollment":25},{"nctId":"NCT05289167","phase":"PHASE1, PHASE2","title":"Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwell Health","startDate":"2022-03-13","conditions":"Graft-versus-host Disease","enrollment":74},{"nctId":"NCT04872218","phase":"PHASE2","title":"Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy","status":"COMPLETED","sponsor":"Philippe Bégin","startDate":"2022-03-01","conditions":"Peanut Allergy","enrollment":14},{"nctId":"NCT04503616","phase":"PHASE1, PHASE2","title":"Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-09-16","conditions":"Graft-versus-host Disease","enrollment":46},{"nctId":"NCT04066114","phase":"PHASE1, PHASE2","title":"Treg Modulation With CD28 and IL-6 Receptor Antagonists","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-11","conditions":"Living-Donor Kidney Transplant, Kidney Transplant Recipients","enrollment":24},{"nctId":"NCT03882008","phase":"PHASE4","title":"A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University of Washington","startDate":"2019-05-23","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT03086343","phase":"PHASE3","title":"A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-05-09","conditions":"Rheumatoid Arthritis (RA)","enrollment":657},{"nctId":"NCT03652961","phase":"PHASE4","title":"Rheumatoid Arthritis Memory B Cells and Abatacept","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2019-06-02","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT01773707","phase":"PHASE2","title":"CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2013-03","conditions":"Abnormal Glucose Tolerance, Type 1 Diabetes","enrollment":212},{"nctId":"NCT03733067","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-11-30","conditions":"CTLA4 Haploinsufficency, Chronic Cytopenia","enrollment":""},{"nctId":"NCT04593940","phase":"PHASE3","title":"Immune Modulators for Treating COVID-19","status":"COMPLETED","sponsor":"Daniel Benjamin","startDate":"2020-10-15","conditions":"Covid19","enrollment":1971},{"nctId":"NCT04255134","phase":"PHASE4","title":"Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)","status":"COMPLETED","sponsor":"St George's, University of London","startDate":"2020-09-07","conditions":"Rheumatoid Arthritis","enrollment":18},{"nctId":"NCT02213068","phase":"PHASE4","title":"Belatacept 3 Month Post Transplant Conversion Study","status":"COMPLETED","sponsor":"Lorenzo Gallon","startDate":"2014-07","conditions":"Transplant; Failure, Kidney, EBV","enrollment":28},{"nctId":"NCT02335606","phase":"","title":"Real World Effectiveness of Abatacept in Rheumatoid Arthritis Patients: a Prospective, Single-arm, Open-label, Multi-center Observational Study in Taiwan","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-08-06","conditions":"Rheumatoid Arthritis","enrollment":213},{"nctId":"NCT00719225","phase":"","title":"A Belatacept Compassionate Use Study for Patients With a Kidney Transplant","status":"NO_LONGER_AVAILABLE","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":"Renal Transplantation","enrollment":""},{"nctId":"NCT01729494","phase":"PHASE4","title":"Belatacept Early Steroid Withdrawal Trial","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2012-09","conditions":"Renal Transplantation","enrollment":316},{"nctId":"NCT03411850","phase":"PHASE2","title":"Sjogrens Syndrome Measured by Ultrasound","status":"UNKNOWN","sponsor":"Arthritis & Rheumatism Associates, P.C.","startDate":"2016-05","conditions":"Sjogren's Syndrome","enrollment":20},{"nctId":"NCT04849533","phase":"PHASE4","title":"Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)","status":"UNKNOWN","sponsor":"University of Cincinnati","startDate":"2021-04-09","conditions":"Kidney Transplant Rejection","enrollment":120},{"nctId":"NCT02592798","phase":"PHASE2","title":"Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-03-09","conditions":"Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease","enrollment":36},{"nctId":"NCT01714817","phase":"PHASE3","title":"Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2013-01-22","conditions":"Lupus Nephritis","enrollment":695},{"nctId":"NCT02152345","phase":"PHASE4","title":"Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients","status":"COMPLETED","sponsor":"Columbia University","startDate":"2014-06","conditions":"Implant or Graft; Rejection","enrollment":57},{"nctId":"NCT01557374","phase":"PHASE4","title":"TOward the Lowest Effective DOse of Abatacept or Tocilizumab","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-04","conditions":"Rheumatoid Arthritis","enrollment":232},{"nctId":"NCT01921218","phase":"PHASE3","title":"Belatacept Therapy for the Failing Renal Allograft","status":"COMPLETED","sponsor":"Andrew B Adams","startDate":"2013-08","conditions":"Failing Renal Allograft","enrollment":13},{"nctId":"NCT03714022","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-11-09","conditions":"Rheumatoid Arthritis","enrollment":140},{"nctId":"NCT02560558","phase":"PHASE4","title":"Bela 8 Week Dosing","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-09","conditions":"Kidney Transplantation","enrollment":166},{"nctId":"NCT00739960","phase":"PHASE2","title":"Safety Study of Abatacept to Treat Refractory Sarcoidosis","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2008-08","conditions":"Sarcoidosis","enrollment":1},{"nctId":"NCT00565773","phase":"PHASE2","title":"Belatacept Post Depletional Repopulation to Facilitate Tolerance","status":"COMPLETED","sponsor":"Allan D Kirk, MD, PhD","startDate":"2007-12","conditions":"Organ Transplantation","enrollment":40},{"nctId":"NCT03375138","phase":"PHASE1","title":"A Study Using Healthy Volunteers Comparing Belatacept Which Has Been Manufactured By 2 Different Processes","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-12-04","conditions":"Healthy Volunteers","enrollment":84},{"nctId":"NCT03084419","phase":"PHASE2","title":"APRIL (AbatacePt in Rheumatoid Arthritis-ILD)","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2018-06-26","conditions":"Rheumatoid Arthritis, Interstitial Lung Disease","enrollment":30},{"nctId":"NCT02130817","phase":"PHASE4","title":"Belatacept in Kidney Transplantation of Moderately Sensitized Patients","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2014-09-24","conditions":"End Stage Renal Disease, Antibody Mediated Rejection","enrollment":""},{"nctId":"NCT02037737","phase":"","title":"Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-09-30","conditions":"Rheumatoid Arthritis","enrollment":153},{"nctId":"NCT00442611","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2008-11","conditions":"Scleroderma, Diffuse, Scleroderma, Systemic","enrollment":10},{"nctId":"NCT02103855","phase":"PHASE4","title":"Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients","status":"COMPLETED","sponsor":"Indiana University","startDate":"2014-06","conditions":"Nephrotoxicity","enrollment":6},{"nctId":"NCT02632890","phase":"","title":"Assessment of the Effectiveness of IV and SC Abatacept (Orencia) Patient Alert Cards in Patients With Rheumatoid Arthritis in a Sample of EU Countries","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-11-29","conditions":"Rheumatoid Arthritis","enrollment":203},{"nctId":"NCT01758198","phase":"PHASE4","title":"Abatacept Post-marketing Clinical Study in Japan","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-04-11","conditions":"Rheumatoid Arthritis","enrollment":405},{"nctId":"NCT00346151","phase":"PHASE2","title":"Belatacept to Prevent Organ Rejection in Kidney Transplant Patients","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-12","conditions":"Renal Transplant","enrollment":5},{"nctId":"NCT02109666","phase":"","title":"Long Term Experience With Abatacept in Routine Clinical Practice","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-03","conditions":"Rheumatoid Arthritis","enrollment":2364},{"nctId":"NCT01837043","phase":"PHASE2","title":"Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function","status":"UNKNOWN","sponsor":"Nair, Vinay, D.O.","startDate":"2013-06","conditions":"Delayed Graft Function, Kidney Transplant","enrollment":90},{"nctId":"NCT00095173","phase":"PHASE3","title":"BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2003-12","conditions":"Juvenile Rheumatoid Arthritis","enrollment":214},{"nctId":"NCT00162201","phase":"PHASE1","title":"An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2003-10","conditions":"Rheumatoid Arthritis","enrollment":16},{"nctId":"NCT00402168","phase":"PHASE2","title":"A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-01","conditions":"Renal Transplant","enrollment":173},{"nctId":"NCT00569803","phase":"PHASE1","title":"Subcutaneous Pharmacokinetics of Belatacept","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-12","conditions":"Transplantation","enrollment":153},{"nctId":"NCT01116427","phase":"PHASE2","title":"A Cooperative Clinical Study of Abatacept in Multiple Sclerosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-09","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":65},{"nctId":"NCT01717846","phase":"PHASE4","title":"Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2012-12","conditions":"Apoptotic DNA Damage, Rheumatoid Arthritis, T-cell Lymphocytosis","enrollment":""},{"nctId":"NCT00468403","phase":"PHASE2","title":"LEA29Y (Belatacept) Emory Edmonton Protocol","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-10","conditions":"Type 1 Diabetes Mellitus","enrollment":10},{"nctId":"NCT00559585","phase":"PHASE3","title":"Methotrexate-Inadequate Response Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-01","conditions":"Rheumatoid Arthritis (RA)","enrollment":2492},{"nctId":"NCT00410410","phase":"PHASE3","title":"A Study of Abatacept in Patients With Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-12","conditions":"Ulcerative Colitis","enrollment":591},{"nctId":"NCT00095147","phase":"PHASE3","title":"Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-02","conditions":"Rheumatoid Arthritis","enrollment":431},{"nctId":"NCT01846975","phase":"PHASE4","title":"Introducing a Single IV Abatacept Treatment in RA Patients Currently Receiving Weekly SC Abatacept to Simulate a Holiday","status":"COMPLETED","sponsor":"Rüdiger B. Müller","startDate":"2013-05","conditions":"Rheumatoid Arthritis","enrollment":49},{"nctId":"NCT01766050","phase":"PHASE4","title":"Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-01","conditions":"Transplant Rejection","enrollment":45},{"nctId":"NCT00455013","phase":"PHASE2","title":"A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-07","conditions":"Disorder Related to Renal Transplantation","enrollment":93},{"nctId":"NCT00254293","phase":"PHASE1, PHASE2","title":"Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-01","conditions":"Rheumatoid Arthritis","enrollment":87},{"nctId":"NCT01001832","phase":"PHASE2, PHASE3","title":"Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Rheumatoid Arthritis","enrollment":118},{"nctId":"NCT00784459","phase":"PHASE2","title":"The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2008-10","conditions":"Atopic Asthma","enrollment":24},{"nctId":"NCT00578448","phase":"PHASE2","title":"Belatacept Pharmacokinetic Trial in Renal Transplantation","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-03","conditions":"Renal Transplantation","enrollment":14},{"nctId":"NCT00035555","phase":"PHASE2","title":"Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2001-03","conditions":"Graft Rejection, Kidney Transplantation, Renal Transplantation","enrollment":230},{"nctId":"NCT00409838","phase":"PHASE3","title":"A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-04","conditions":"Rheumatoid Arthritis","enrollment":113},{"nctId":"NCT00534313","phase":"PHASE2","title":"Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2007-11","conditions":"Psoriatic Arthritis","enrollment":191},{"nctId":"NCT00162266","phase":"PHASE2","title":"Abatacept With Methotrexate- Phase IIB","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2000-10","conditions":"Rheumatoid Arthritis","enrollment":524},{"nctId":"NCT00124982","phase":"PHASE3","title":"Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-04","conditions":"Rheumatoid Arthritis","enrollment":1286},{"nctId":"NCT00420199","phase":"PHASE3","title":"A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-05","conditions":"Active Rheumatoid Arthritis","enrollment":50},{"nctId":"NCT00048568","phase":"PHASE3","title":"A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-12","conditions":"Rheumatoid Arthritis","enrollment":1250},{"nctId":"NCT00048932","phase":"PHASE3","title":"A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-12","conditions":"Rheumatoid Arthritis","enrollment":1795},{"nctId":"NCT00048581","phase":"PHASE3","title":"Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-12","conditions":"Rheumatoid Arthritis","enrollment":738},{"nctId":"NCT00989235","phase":"PHASE3","title":"Substudy - Low Dose of Abatacept in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-04","conditions":"Rheumatoid Arthritis","enrollment":108},{"nctId":"NCT00345748","phase":"PHASE2","title":"A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving Methotrexate","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-06","conditions":"Rheumatoid Arthritis","enrollment":194},{"nctId":"NCT00279734","phase":"PHASE1","title":"Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-08","conditions":"Rheumatoid Arthritis","enrollment":80},{"nctId":"NCT00122382","phase":"PHASE3","title":"Remission and Joint Damage Progression in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-07","conditions":"Rheumatoid Arthritis","enrollment":1052},{"nctId":"NCT00406653","phase":"PHASE3","title":"A Study of Abatacept in Patients With Active Crohn's Disease","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2006-12","conditions":"Crohn's Disease","enrollment":451}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Switch from SC to IV Abatacept and back"],"phase":"marketed","status":"active","brandName":"IV Abatacept","genericName":"IV Abatacept","companyName":"Rüdiger B. Müller","companyId":"r-diger-b-m-ller","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation. Used for Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}